Юдин Денис Иванович

Osimertinib for the first-line treatment of EGFR-positive non-small cell lung cancer

K. Laktionov, A. Egorova, E. Reutova, 2019, Journal of Modern Oncology.

New possibilities in the treatment of EGFR mutation-positive non-small-cell lung cancer patients after the progression on a 1st and 2nd generation EGFR tyrosine kinase inhibitors

I. Demidova, A. R. Zaretsky, K. Laktionov, 2018, Journal of Modern Oncology.